Abiomed wins FDA approval for flagship Impella 2.5 heart pump

Abiomed shares jump after hours on news that the FDA granted pre-market approval for its flagship Impella 2.5 heart pump.

Abiomed (NSDQ:ABMD) yesterday won pre-market approval from the FDA for its flagship Impella 2.5 heart pump, sending shares up 2% in after-market trading.

Food & Drug Administration (FDA), Abiomed Inc.

News Well, Cardiac Assist Devices, Pre-Market Approval (PMA), Regulatory/Compliance, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1bpReFu